Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
Melphalan has been evaluated against a series of seven childhood rhabdomyosarcomas, each derived from a different patient and maintained in vivo as xenografts in immune-deprived mice. Six lines were derived from untreated tumors and one from a patient refractory to conventional therapy. At the maximum tolerated dose (LD10) a single administration of melphalan caused complete regressions of advanced tumor in six of seven lines, including xenografts derived from the refractory patient. This agent demonstrated activity over a broad range of doses, and was considerably more active than vincristine, cyclophosphamide, doxorubicin, and dactinomycin in the model.
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002648:Child; D005260:Female; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000473:pathology; D014183:Transplantation, Heterologous
D008558:Melphalan